Summary
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.
According to APO Research, The global Microbiome Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Microbiome Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Microbiome Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Drugs include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Microbiome Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Microbiome Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Microbiome Drugs revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Microbiome Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Microbiome Drugs revenue, projected growth trends, production technology, application and end-user industry.
Microbiome Drugs segment by Company
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Interxon
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
AOBiome
Rebiotix
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Osel
Microbiome Drugs segment by Type
Oral Dosage Form
Enteric Capsules
Microbiome Drugs segment by Symptom
Gastrointestinal Disorders
Autoimmune Disorders
Diabetes
Cancer
Others
Microbiome Drugs segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Microbiome Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Microbiome Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Microbiome Drugs Market by Type
1.2.1 Global Microbiome Drugs Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Oral Dosage Form
1.2.3 Enteric Capsules
1.3 Microbiome Drugs Market by Symptom
1.3.1 Global Microbiome Drugs Market Size by Symptom, 2019 VS 2023 VS 2030
1.3.2 Gastrointestinal Disorders
1.3.3 Autoimmune Disorders
1.3.4 Diabetes
1.3.5 Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Microbiome Drugs Market Dynamics
2.1 Microbiome Drugs Industry Trends
2.2 Microbiome Drugs Industry Drivers
2.3 Microbiome Drugs Industry Opportunities and Challenges
2.4 Microbiome Drugs Industry Restraints
3 Global Growth Perspective
3.1 Global Microbiome Drugs Market Perspective (2019-2030)
3.2 Global Microbiome Drugs Growth Trends by Region
3.2.1 Global Microbiome Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Microbiome Drugs Market Size by Region (2019-2024)
3.2.3 Global Microbiome Drugs Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Microbiome Drugs Revenue by Players
4.1.1 Global Microbiome Drugs Revenue by Players (2019-2024)
4.1.2 Global Microbiome Drugs Revenue Market Share by Players (2019-2024)
4.1.3 Global Microbiome Drugs Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Microbiome Drugs Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Microbiome Drugs Key Players Headquarters & Area Served
4.4 Global Microbiome Drugs Players, Product Type & Application
4.5 Global Microbiome Drugs Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Microbiome Drugs Market CR5 and HHI
4.6.2 Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2023
4.6.3 2023 Microbiome Drugs Tier 1, Tier 2, and Tier 3
5 Microbiome Drugs Market Size by Type
5.1 Global Microbiome Drugs Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Microbiome Drugs Revenue by Type (2019-2030)
5.3 Global Microbiome Drugs Revenue Market Share by Type (2019-2030)
6 Microbiome Drugs Market Size by Application
6.1 Global Microbiome Drugs Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Microbiome Drugs Revenue by Application (2019-2030)
6.3 Global Microbiome Drugs Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Comapny Information
7.1.2 Seres Therapeutics Business Overview
7.1.3 Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.1.4 Seres Therapeutics Microbiome Drugs Product Portfolio
7.1.5 Seres Therapeutics Recent Developments
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Comapny Information
7.2.2 Assembly Biosciences Business Overview
7.2.3 Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.2.4 Assembly Biosciences Microbiome Drugs Product Portfolio
7.2.5 Assembly Biosciences Recent Developments
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Comapny Information
7.3.2 Synthetic Biologics Business Overview
7.3.3 Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.3.4 Synthetic Biologics Microbiome Drugs Product Portfolio
7.3.5 Synthetic Biologics Recent Developments
7.4 Interxon
7.4.1 Interxon Comapny Information
7.4.2 Interxon Business Overview
7.4.3 Interxon Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.4.4 Interxon Microbiome Drugs Product Portfolio
7.4.5 Interxon Recent Developments
7.5 PureTech
7.5.1 PureTech Comapny Information
7.5.2 PureTech Business Overview
7.5.3 PureTech Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.5.4 PureTech Microbiome Drugs Product Portfolio
7.5.5 PureTech Recent Developments
7.6 Synlogic
7.6.1 Synlogic Comapny Information
7.6.2 Synlogic Business Overview
7.6.3 Synlogic Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.6.4 Synlogic Microbiome Drugs Product Portfolio
7.6.5 Synlogic Recent Developments
7.7 Enterome BioScience
7.7.1 Enterome BioScience Comapny Information
7.7.2 Enterome BioScience Business Overview
7.7.3 Enterome BioScience Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.7.4 Enterome BioScience Microbiome Drugs Product Portfolio
7.7.5 Enterome BioScience Recent Developments
7.8 4D Pharma
7.8.1 4D Pharma Comapny Information
7.8.2 4D Pharma Business Overview
7.8.3 4D Pharma Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.8.4 4D Pharma Microbiome Drugs Product Portfolio
7.8.5 4D Pharma Recent Developments
7.9 Second Genome
7.9.1 Second Genome Comapny Information
7.9.2 Second Genome Business Overview
7.9.3 Second Genome Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.9.4 Second Genome Microbiome Drugs Product Portfolio
7.9.5 Second Genome Recent Developments
7.10 AOBiome
7.10.1 AOBiome Comapny Information
7.10.2 AOBiome Business Overview
7.10.3 AOBiome Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.10.4 AOBiome Microbiome Drugs Product Portfolio
7.10.5 AOBiome Recent Developments
7.11 Rebiotix
7.11.1 Rebiotix Comapny Information
7.11.2 Rebiotix Business Overview
7.11.3 Rebiotix Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.11.4 Rebiotix Microbiome Drugs Product Portfolio
7.11.5 Rebiotix Recent Developments
7.12 Metabiomics
7.12.1 Metabiomics Comapny Information
7.12.2 Metabiomics Business Overview
7.12.3 Metabiomics Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.12.4 Metabiomics Microbiome Drugs Product Portfolio
7.12.5 Metabiomics Recent Developments
7.13 Ritter Pharmaceuticals
7.13.1 Ritter Pharmaceuticals Comapny Information
7.13.2 Ritter Pharmaceuticals Business Overview
7.13.3 Ritter Pharmaceuticals Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.13.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
7.13.5 Ritter Pharmaceuticals Recent Developments
7.14 Symberix
7.14.1 Symberix Comapny Information
7.14.2 Symberix Business Overview
7.14.3 Symberix Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.14.4 Symberix Microbiome Drugs Product Portfolio
7.14.5 Symberix Recent Developments
7.15 OpenBiome
7.15.1 OpenBiome Comapny Information
7.15.2 OpenBiome Business Overview
7.15.3 OpenBiome Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.15.4 OpenBiome Microbiome Drugs Product Portfolio
7.15.5 OpenBiome Recent Developments
7.16 Azitra
7.16.1 Azitra Comapny Information
7.16.2 Azitra Business Overview
7.16.3 Azitra Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.16.4 Azitra Microbiome Drugs Product Portfolio
7.16.5 Azitra Recent Developments
7.17 Osel
7.17.1 Osel Comapny Information
7.17.2 Osel Business Overview
7.17.3 Osel Microbiome Drugs Revenue and Gross Margin (2019-2024)
7.17.4 Osel Microbiome Drugs Product Portfolio
7.17.5 Osel Recent Developments
8 North America
8.1 North America Microbiome Drugs Revenue (2019-2030)
8.2 North America Microbiome Drugs Revenue by Type (2019-2030)
8.2.1 North America Microbiome Drugs Revenue by Type (2019-2024)
8.2.2 North America Microbiome Drugs Revenue by Type (2025-2030)
8.3 North America Microbiome Drugs Revenue Share by Type (2019-2030)
8.4 North America Microbiome Drugs Revenue by Symptom (2019-2030)
8.4.1 North America Microbiome Drugs Revenue by Symptom (2019-2024)
8.4.2 North America Microbiome Drugs Revenue by Symptom (2025-2030)
8.5 North America Microbiome Drugs Revenue Share by Symptom (2019-2030)
8.6 North America Microbiome Drugs Revenue by Country
8.6.1 North America Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Microbiome Drugs Revenue by Country (2019-2024)
8.6.3 North America Microbiome Drugs Revenue by Country (2025-2030)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Microbiome Drugs Revenue (2019-2030)
9.2 Europe Microbiome Drugs Revenue by Type (2019-2030)
9.2.1 Europe Microbiome Drugs Revenue by Type (2019-2024)
9.2.2 Europe Microbiome Drugs Revenue by Type (2025-2030)
9.3 Europe Microbiome Drugs Revenue Share by Type (2019-2030)
9.4 Europe Microbiome Drugs Revenue by Symptom (2019-2030)
9.4.1 Europe Microbiome Drugs Revenue by Symptom (2019-2024)
9.4.2 Europe Microbiome Drugs Revenue by Symptom (2025-2030)
9.5 Europe Microbiome Drugs Revenue Share by Symptom (2019-2030)
9.6 Europe Microbiome Drugs Revenue by Country
9.6.1 Europe Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Microbiome Drugs Revenue by Country (2019-2024)
9.6.3 Europe Microbiome Drugs Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Microbiome Drugs Revenue (2019-2030)
10.2 China Microbiome Drugs Revenue by Type (2019-2030)
10.2.1 China Microbiome Drugs Revenue by Type (2019-2024)
10.2.2 China Microbiome Drugs Revenue by Type (2025-2030)
10.3 China Microbiome Drugs Revenue Share by Type (2019-2030)
10.4 China Microbiome Drugs Revenue by Symptom (2019-2030)
10.4.1 China Microbiome Drugs Revenue by Symptom (2019-2024)
10.4.2 China Microbiome Drugs Revenue by Symptom (2025-2030)
10.5 China Microbiome Drugs Revenue Share by Symptom (2019-2030)
11 Asia (Excluding China)
11.1 Asia Microbiome Drugs Revenue (2019-2030)
11.2 Asia Microbiome Drugs Revenue by Type (2019-2030)
11.2.1 Asia Microbiome Drugs Revenue by Type (2019-2024)
11.2.2 Asia Microbiome Drugs Revenue by Type (2025-2030)
11.3 Asia Microbiome Drugs Revenue Share by Type (2019-2030)
11.4 Asia Microbiome Drugs Revenue by Symptom (2019-2030)
11.4.1 Asia Microbiome Drugs Revenue by Symptom (2019-2024)
11.4.2 Asia Microbiome Drugs Revenue by Symptom (2025-2030)
11.5 Asia Microbiome Drugs Revenue Share by Symptom (2019-2030)
11.6 Asia Microbiome Drugs Revenue by Country
11.6.1 Asia Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Microbiome Drugs Revenue by Country (2019-2024)
11.6.3 Asia Microbiome Drugs Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Microbiome Drugs Revenue (2019-2030)
12.2 MEALA Microbiome Drugs Revenue by Type (2019-2030)
12.2.1 MEALA Microbiome Drugs Revenue by Type (2019-2024)
12.2.2 MEALA Microbiome Drugs Revenue by Type (2025-2030)
12.3 MEALA Microbiome Drugs Revenue Share by Type (2019-2030)
12.4 MEALA Microbiome Drugs Revenue by Symptom (2019-2030)
12.4.1 MEALA Microbiome Drugs Revenue by Symptom (2019-2024)
12.4.2 MEALA Microbiome Drugs Revenue by Symptom (2025-2030)
12.5 MEALA Microbiome Drugs Revenue Share by Symptom (2019-2030)
12.6 MEALA Microbiome Drugs Revenue by Country
12.6.1 MEALA Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Microbiome Drugs Revenue by Country (2019-2024)
12.6.3 MEALA Microbiome Drugs Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
List of Tables
Table 1. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Oral Dosage Form Major Manufacturers
Table 2. Enteric Capsules Major Manufacturers
Table 3. Global Microbiome Drugs Market Size Growth Rate by Symptom (US$ Million), 2019 VS 2023 VS 2030
Table 4. Gastrointestinal Disorders Major Manufacturers
Table 5. Autoimmune Disorders Major Manufacturers
Table 6. Diabetes Major Manufacturers
Table 7. Cancer Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Microbiome Drugs Industry Trends
Table 10. Microbiome Drugs Industry Drivers
Table 11. Microbiome Drugs Industry Opportunities and Challenges
Table 12. Microbiome Drugs Industry Restraints
Table 13. Global Microbiome Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Microbiome Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Microbiome Drugs Market Share by Region (2019-2024)
Table 16. Global Microbiome Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Microbiome Drugs Market Share by Region (2025-2030)
Table 18. Global Microbiome Drugs Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Microbiome Drugs Revenue Market Share by Players (2019-2024)
Table 20. Global Microbiome Drugs Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Microbiome Drugs Key Players Headquarters & Area Served
Table 22. Global Microbiome Drugs Players, Product Type & Application
Table 23. Global Microbiome Drugs Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Microbiome Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Microbiome Drugs Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Microbiome Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Microbiome Drugs Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Microbiome Drugs Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Microbiome Drugs Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Microbiome Drugs Revenue by Symptom 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Microbiome Drugs Revenue by Symptom (2019-2024) & (US$ Million)
Table 33. Global Microbiome Drugs Revenue by Symptom (2025-2030) & (US$ Million)
Table 34. Global Microbiome Drugs Revenue Market Share by Symptom (2019-2024) & (US$ Million)
Table 35. Global Microbiome Drugs Revenue Market Share by Symptom (2025-2030) & (US$ Million)
Table 36. Seres Therapeutics Company Information
Table 37. Seres Therapeutics Business Overview
Table 38. Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. Seres Therapeutics Microbiome Drugs Product Portfolio
Table 40. Seres Therapeutics Recent Development
Table 41. Assembly Biosciences Company Information
Table 42. Assembly Biosciences Business Overview
Table 43. Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Assembly Biosciences Microbiome Drugs Product Portfolio
Table 45. Assembly Biosciences Recent Development
Table 46. Synthetic Biologics Company Information
Table 47. Synthetic Biologics Business Overview
Table 48. Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Synthetic Biologics Microbiome Drugs Product Portfolio
Table 50. Synthetic Biologics Recent Development
Table 51. Interxon Company Information
Table 52. Interxon Business Overview
Table 53. Interxon Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Interxon Microbiome Drugs Product Portfolio
Table 55. Interxon Recent Development
Table 56. PureTech Company Information
Table 57. PureTech Business Overview
Table 58. PureTech Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. PureTech Microbiome Drugs Product Portfolio
Table 60. PureTech Recent Development
Table 61. Synlogic Company Information
Table 62. Synlogic Business Overview
Table 63. Synlogic Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. Synlogic Microbiome Drugs Product Portfolio
Table 65. Synlogic Recent Development
Table 66. Enterome BioScience Company Information
Table 67. Enterome BioScience Business Overview
Table 68. Enterome BioScience Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Enterome BioScience Microbiome Drugs Product Portfolio
Table 70. Enterome BioScience Recent Development
Table 71. 4D Pharma Company Information
Table 72. 4D Pharma Business Overview
Table 73. 4D Pharma Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. 4D Pharma Microbiome Drugs Product Portfolio
Table 75. 4D Pharma Recent Development
Table 76. Second Genome Company Information
Table 77. Second Genome Business Overview
Table 78. Second Genome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. Second Genome Microbiome Drugs Product Portfolio
Table 80. Second Genome Recent Development
Table 81. AOBiome Company Information
Table 82. AOBiome Business Overview
Table 83. AOBiome Microbiome Drugs Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. AOBiome Microbiome Drugs Product Portfolio
Table 85. AOBiome Recent Development
Table 86. Rebiotix Company Information
Table 87. Rebiotix Business Overview
Table 88. Rebiotix Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. Rebiotix Microbiome Drugs Product Portfolio
Table 90. Rebiotix Recent Development
Table 91. Metabiomics Company Information
Table 92. Metabiomics Business Overview
Table 93. Metabiomics Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Metabiomics Microbiome Drugs Product Portfolio
Table 95. Metabiomics Recent Development
Table 96. Ritter Pharmaceuticals Company Information
Table 97. Ritter Pharmaceuticals Business Overview
Table 98. Ritter Pharmaceuticals Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
Table 100. Ritter Pharmaceuticals Recent Development
Table 101. Symberix Company Information
Table 102. Symberix Business Overview
Table 103. Symberix Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Symberix Microbiome Drugs Product Portfolio
Table 105. Symberix Recent Development
Table 106. OpenBiome Company Information
Table 107. OpenBiome Business Overview
Table 108. OpenBiome Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. OpenBiome Microbiome Drugs Product Portfolio
Table 110. OpenBiome Recent Development
Table 111. Azitra Company Information
Table 112. Azitra Business Overview
Table 113. Azitra Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Azitra Microbiome Drugs Product Portfolio
Table 115. Azitra Recent Development
Table 116. Osel Company Information
Table 117. Osel Business Overview
Table 118. Osel Microbiome Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Osel Microbiome Drugs Product Portfolio
Table 120. Osel Recent Development
Table 121. North America Microbiome Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 122. North America Microbiome Drugs Revenue by Symptom (2019-2024) & (US$ Million)
Table 123. North America Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 124. North America Microbiome Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 125. North America Microbiome Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 126. Europe Microbiome Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 127. Europe Microbiome Drugs Revenue by Symptom (2019-2024) & (US$ Million)
Table 128. Europe Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 129. Europe Microbiome Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 130. Europe Microbiome Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 131. China Microbiome Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 132. China Microbiome Drugs Revenue by Symptom (2019-2024) & (US$ Million)
Table 133. Asia Microbiome Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 134. Asia Microbiome Drugs Revenue by Symptom (2019-2024) & (US$ Million)
Table 135. Asia Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 136. Asia Microbiome Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 137. Asia Microbiome Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 138. MEALA Microbiome Drugs Revenue by Type (2019-2024) & (US$ Million)
Table 139. MEALA Microbiome Drugs Revenue by Symptom (2019-2024) & (US$ Million)
Table 140. MEALA Microbiome Drugs Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 141. MEALA Microbiome Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 142. MEALA Microbiome Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 143. Research Programs/Design for This Report
Table 144. Authors List of This Report
Table 145. Secondary Sources
Table 146. Primary Sources
List of Figures
Figure 1. Microbiome Drugs Product Picture
Figure 2. Global Microbiome Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Microbiome Drugs Market Size Share 2019 VS 2023 VS 2030
Figure 4. Oral Dosage Form Picture
Figure 5. Enteric Capsules Picture
Figure 6. Global Microbiome Drugs Market Size Growth Rate by Symptom (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global Microbiome Drugs Market Size Share 2019 VS 2023 VS 2030
Figure 8. Gastrointestinal Disorders Picture
Figure 9. Autoimmune Disorders Picture
Figure 10. Diabetes Picture
Figure 11. Cancer Picture
Figure 12. Others Picture
Figure 13. Global Microbiome Drugs Market Size (US$ Million) & (2019-2030)
Figure 14. Global Microbiome Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Microbiome Drugs Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Microbiome Drugs Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Microbiome Drugs Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Microbiome Drugs Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Microbiome Drugs Revenue Market Share by Type (2019-2030)
Figure 21. Global Microbiome Drugs Revenue by Symptom (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Microbiome Drugs Revenue Market Share by Symptom (2019 VS 2023 VS 2030)
Figure 23. Global Microbiome Drugs Revenue Market Share by Symptom (2019-2030)
Figure 24. North America Microbiome Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Microbiome Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Microbiome Drugs Revenue Share by Type (2019-2030)
Figure 27. North America Microbiome Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Microbiome Drugs Revenue Share by Application (2019-2030)
Figure 29. North America Microbiome Drugs Revenue Share by Country (2019-2030)
Figure 30. United States Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Microbiome Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Microbiome Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Microbiome Drugs Revenue Share by Type (2019-2030)
Figure 35. Europe Microbiome Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Microbiome Drugs Revenue Share by Application (2019-2030)
Figure 37. Europe Microbiome Drugs Revenue Share by Country (2019-2030)
Figure 38. Germany Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Microbiome Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Microbiome Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Microbiome Drugs Revenue Share by Type (2019-2030)
Figure 47. China Microbiome Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Microbiome Drugs Revenue Share by Application (2019-2030)
Figure 49. Asia Microbiome Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Microbiome Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Microbiome Drugs Revenue Share by Type (2019-2030)
Figure 52. Asia Microbiome Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Microbiome Drugs Revenue Share by Application (2019-2030)
Figure 54. Asia Microbiome Drugs Revenue Share by Country (2019-2030)
Figure 55. Japan Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. MEALA Microbiome Drugs Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 62. MEALA Microbiome Drugs Revenue by Type (2025-2030) & (US$ Million)
Figure 63. MEALA Microbiome Drugs Revenue Share by Type (2019-2030)
Figure 64. MEALA Microbiome Drugs Revenue by Application (2025-2030) & (US$ Million)
Figure 65. MEALA Microbiome Drugs Revenue Share by Application (2019-2030)
Figure 66. MEALA Microbiome Drugs Revenue Share by Country (2019-2030)
Figure 67. Mexico Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. South Korea Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Brazil Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Israel Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Argentina Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Colombia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Turkey Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Saudi Arabia Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. UAE Microbiome Drugs Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Years Considered
Figure 77. Research Process
Figure 78. Key Executives Interviewed
